The Clinical study of the combination of tear biomarkers in the diagnosis of ocular chronic graft-versus-host disease

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2200062516

Enrollment

Unknown

Registered

2022-08-10

Start date

2022-08-01

Completion date

Unknown

Last updated

2023-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ocular Graft Versus Host Disease

Interventions

Gold Standard:International Chronic Ocular Graft-vs-Host-Disease (GVHD) Consensus Group: Proposed Diagnostic Criteria for Chronic GVHD (Part I):the parameters for diagnosis include 1) Ocular Surface D

Index test:Tear biomarkers

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: From July 2022 to July 2024, in our center,post-allo-HSCT patients over 18 years old are willing to participate in the study by themselves and sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. Active infection in the eyes; 2. Other diseases than ocular GVHD; 3. Unwilling to cooperate; 4. Ocular operation within three months; 5. Pregnancy or lactation; 6. Other conditions researchers consider not fit this trial; 7. Unable to complete the study; 8. Refuse to sign informed consent.

Design outcomes

Primary

Measure	Time frame
Tear cytokines / chemokines;	—

Countries

China

Contacts

Public ContactXi Zhang

The Hematology Department of the Second Affiliated Hospital of Army Medical University

zhangxxi@sina.com+86 13808310064

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 8, 2026